A double-blind and placebo-controlled study in 37 patients with moderate-to-severe active Crohn's disease (CD) showed that therapy with recombinant GH (Somatropin, Humatrope, Eli Lilly, Indianapolis, USA) may be a beneficial treatment. This evidence concerns the gene GH1 and Crohn disease.